Page 177 - 2018_09-Mondo

Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle
cell disease: interim results
Farid Boulad,1,2 Tsiporah Shore,3 Koen van Besien,3 Caterina Minniti,4 Mihaela Barbu-Stevanovic,5 Sylvie Wiener Fedus,6 Fabiana Perna,2 June Greenberg,7 Danielle Guarneri,7 Vijay Nandi,5 Audrey Mauguen,8 Karina Yazdanbakhsh,5 Michel Sadelain2 and Patricia A. Shi4,5
1Department of Pediatrics, BMT Service, Memorial Sloan Kettering Cancer Center, New York; 2Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York; 3Bone Marrow and Hematopoietic Stem Cell Transplant Program, Weill Cornell Medicine/ New York Presbyterian Hospital, New York; 4Sickle Cell Program, Division of Hematology, Albert Einstein College of Medicine, Bronx; 5Lindsley F. Kimball Research Institute, New York Blood Center, NY; 6Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York; 7Division of Hematology and Oncology, Weill Cornell Medicine /New York Presbyterian Hospital, NY and 8Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
doi:10.3324/haematol.2018.199414
©2018 Ferrata Storti Foundation
Our target goal of mobilizing at least 30 CD34+ cells/μL was, however, reached in only 50% of patients given the plerixafor dose of 80 μg/kg, 33% of patients given 160 μg/kg, and 33% of patients given 240 μg/kg.
An incorrect version of sentence appared on May 2018 Issue, pages 773.
The corrected version of sentence is published below.
Our target goal of mobilizing at least 30 CD34+ cells/μL was, however, reached in only 50% of patients given the plerixafor dose of 80 μg/kg, 67% of patients given 160 μg/kg, and 67% of patients given 240 μg/kg.
An incorrect version of sentence appared on May 2018 Issue, pages 777.
Eight of 15 patients (53%) with SCD treated with plerixafor reached the peripheral blood CD34 cell target count of at least 30 CD34+ cells/μL, including three of six patients treated at a dose of 240 μg/kg.
The corrected version of sentence is published below.
Nine of 15 patients (60%) with SCD treated with plerixafor reached the peripheral blood CD34 cell target count of at least 30 CD34+ cells/μL, including four of six patients treated at a dose of 240 μg/kg.
haematologica | 2018; 103(9)
1577
ERRATA CORRIGE